Day: October 1, 2021

STAT+: Three generic drug makers to pay $450 million to settle civil price fixing charges

Three generic drug makers agreed to pay nearly $450 million to resolve civil allegations that they conspired to fix prices for numerous medications, which caused U.S. federal government health care programs and their beneficiaries to overpay for the treatments. In each instance, the companies — the Sandoz unit at Novartis (NVS), Taro Pharmaceuticals and Apotex […]

STAT+: Prosecutors allege two individuals preyed on those searching for addiction recovery help

Two men were indicted this week for allegedly running a scam in which they preyed on New England residents searching for addiction recovery help, offering to hook them up with top notch treatment in sunny Florida, but sending them off to questionable facilities on false insurance policies. Their promises were lies, and they received payouts […]

For the first time, WHO committee recommends action on high-priced essential medicines

For the first time, a World Health Organization committee has recommended the global agency form a working group to explore policies for contending with the high prices of medicines that are considered essential, but unaffordable in many low and middle-income countries. The suggestion was made in the latest report about treatments to be added to […]

STAT+: Up and down the ladder: The latest comings and goings

Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. Continue to STAT+ to read […]

STAT+: Pharmalittle: Merck’s Covid-19 pill reduced hospitalizations in a study; Dems start scaling back drug-pricing plans

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda, once again, is rather modest. We plan to check in on the Pharmalot ancestors, catch up on some reading, and watch some footie […]

A new surgical robot is smaller, nimbler, and cheaper, its maker claims. But will it be better for patients?

The surgical robot market, long dominated by one company, has a new entrant hoping to disrupt the industry with a more immersive, 3D experience for surgeons — even as the need for surgical robots in most procedures remains hotly debated. Robot-assisted surgery has boomed in the past 20 years, led by Intuitive, the company that […]

STAT+: Why the medical AI company Dascena hopes hard evidence will separate it from its rivals

Think of it as digital health’s chicken and egg problem. Which comes first: national distribution of your algorithm, or clinical evidence that it works? For a startup, it is almost impossible to have one without the other. The medical artificial intelligence company Dascena is among many early-stage companies in the throes of this debate. It […]

STAT+: In the ‘fail fast’ world of biotech, ‘offboarding’ is just as important as onboarding

In today’s biotech job market — where competition for people with in-demand experience is fiercer than ever — it’s become critical for biotech startups and venture capitalists to ensure people have a smooth exit when their companies downsize or go under. Biotech is a notoriously small world, especially in regions like Boston and the Bay […]

Opinion: For abortion care, physicians may need to step aside to support patients

I have come to think that people who provide abortion care are models of the ideal health care provider. Practicing this stigmatized work requires them to be nonjudgmental, ask open-ended questions and let patients take the lead. In the face of a building wave of restrictions against abortion, I’ve seen providers move heaven and earth […]

Merck’s antiviral pill reduces hospitalization of Covid patients, a possible game-changer for treatment

An investigational antiviral pill reduced the chances that patients newly diagnosed with Covid-19 would be hospitalized by about 50%, a finding that could give doctors a desperately needed new way to treat the sick, the drug maker Merck announced Friday. A five-day course of molnupiravir, developed by Merck and Ridgeback Biotherapeutics, reduced both hospitalization and […]

Scroll to top